title: Modulation of alcohol preference by NMDA antagonists in male rats.
abstract: Chronic alcoholization by alcohol inhalation was used to study the properties of magnesium, a non-competitive NMDA receptor antagonist, and CGP 39551, a competitive NMDA receptor antagonist, on behavioural dependence as estimated by the free-choice paradigm [alcohol 10% (v/v) vs. water], on the hypermotility after alcohol withdrawal, and finally on the cortical vascularization. The first experimental group received the drugs per os during the whole alcoholization period. Magnesium (20 mg/kg/day) decreased the alcohol dependence while CGP 39551 (5 and 10 mg/kg/day) increased, in a dose-dependent manner, the dependence to alcohol. A second group of animals received the same drugs at the same dosages, not simultaneously during chronic alcoholization, but immediately after alcoholization in one shot i.p. injection. In this case, rats receiving 5 mg/kg CGP 39551 never showed any dependence towards alcohol, while 10 mg/kg CGP 39551 or 20 mg/kg magnesium prolonged the number of days of alcohol dependence. These results thus indicate the close interaction between NMDA receptor function and dependence for alcohol. Magnesium had no effects on hypermotility, while CGP 39551-treated animals presented a decrease in the hypermotility observed after alcohol withdrawal. Neither drug affected the hypervascularization accompanying the chronic alcoholization.
authors.affiliation: Université Catholique de Louvain, Lab. Psychobiologie, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Lamblin
authors.forename: D
authors.initials: D
authors.lastname: Deuceuninck
authors.forename: P
authors.initials: P
authors.lastname: De Witte
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal; D001921:Brain / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D002755:Choice Behavior; D000431:Ethanol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008274:Magnesium / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects* / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000378:metabolism
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; C064540:CGP 39551; D000431:Ethanol; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; D008274:Magnesium